Veröffentlichungsdatum: 30 Januar 2019
Projektträger – zwischengeschaltetes Finanzinstitut
The project concerns Research and Development (R&D) investments in core therapeutic areas to be implemented in the period 2018-2020 .
The investments cover RDI expenditures of the clinical and regulatory development of Orion's product range. By co-investing in this project, the EIB contributes to make treatments available for diseases that are a high priority for the healthcare system and enables the creation of scientific knowledge.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 100 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 336 million
All of the project activities are expected to be carried out in existing facilities and laboratories without changing their already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU, as amended. Nevertheless, the Bank's services will review during the project appraisal whether any of the investments require an EIA, as well as any other environmental details of the project.
The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not subject to the EU directives on procurement.
Unterzeichnet - 18/01/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).